| RESEARCH
STATUS
|
| Clinical
data |
Ongoing |
| Preclinical
data |
Available |
| Short
term Toxicity data |
Available |
| Long
term Toxicity date |
Pending |
| Phytochemical
standardization |
Pending |
|
Type II Diabetes
Supports Healthy cholesterol levels
Diabetes is the seventh-leading cause of death and about 30 million
people throughout the world suffer from diabetes mellitus. Drug
intolerance, hypersensitivity and resistance to insulin etc. makes
it all the more important to search for safe, effective and cheaper
remedies. Worldwide, there is an increasing interest in the use
of herbs/plants as most of the modern drugs are costly and tagged
with serious side effects.
Derived from natural source, Diabcin demonstrated significant antihyperglycemic
effect in alloxan induced diabetic mice. Diabcin showed a significant
decrease in triglyceride, cholesterol and urea levels as compared
with diabetic control animals and hence is helpful in correcting
complications of lipid profile i.e. hypercholesterolemia which quite
often coexist in some diabetics.
Dosage / Suggested Use: 1 capsule tid
PHARMACOLOGICAL EFFECTS OF DIABCIN
Our Product Specification
| Model
T |
Dose |
Results |
| Diabetes
Type II - Oral Glucose Tolerance Test |
Diabcin
(300 mg/kg b.w.) / Glibenclamide as standard (3mg/kg) |
Administration
of the Chiraza brings down the glucose level to 87.16
mg/dl at 180 mins which is comparable with Glibenclamide
(76.66 mg/dl) |
| Diabetes
Type II - Long term 30 days study in Alloxan induced male
swiss albino mice |
Diabcin
(600 mg/kg b.w.) |
An
antihyperglycemic effect was observed at 10th, 20th and
30th day with 600-mg/kg body weight of the formulation
resulting in the glucose level being reduced to 12.91%
(p<0.5), 28.75% (p<0.05), 31.20% (p<0.02) respectively. |
| Diabcin
showed a significant decrease in triglyceride 112.27%
(P<0.001), cholesterol 83.37% (P<0.05) and urea
24.52% as compared with diabetic control animals. |
|
|
|
CLINICAL STUDY OUTLINE
Design: Prospective Multi-Centric
GCP Compliant Study
Objective: To investigate the safety,
tolerability and effect of DIABCIN CAPSULES - "A Dietary
Supplement" as a mono therapy in management of patients
with Type 2/ Non-Insulin Dependent Diabetes Mellitus.
Treatment Duration: 90 days
Number of Subjects: 30
SAFETY
Acute Oral Toxicity study
The LD50 established at > 2 gm/kg
These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, cure,
treat or prevent any disease. |
| |
|
|
|
